These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 23078245)
1. Inhibitors of LRRK2 kinase activity to probe the treatment option in Parkinson's disease. Rautio J J Med Chem; 2012 Nov; 55(22):9414-5. PubMed ID: 23078245 [No Abstract] [Full Text] [Related]
2. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease. Gilligan PJ Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719 [TBL] [Abstract][Full Text] [Related]
3. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184 [TBL] [Abstract][Full Text] [Related]
4. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Ray S; Liu M Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508 [TBL] [Abstract][Full Text] [Related]
7. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease? Taymans JM Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782 [TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of LRRK2: from kinase to substrate. Lobbestael E; Baekelandt V; Taymans JM Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873 [TBL] [Abstract][Full Text] [Related]
9. Kinases as targets for Parkinson's disease: from genetics to therapy. Vancraenenbroeck R; Lobbestael E; Maeyer MD; Baekelandt V; Taymans JM CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):724-40. PubMed ID: 21838679 [TBL] [Abstract][Full Text] [Related]
10. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? Rudenko IN; Chia R; Cookson MR BMC Med; 2012 Feb; 10():20. PubMed ID: 22361010 [TBL] [Abstract][Full Text] [Related]
12. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. West AB Mov Disord; 2015 Feb; 30(2):180-9. PubMed ID: 25448543 [TBL] [Abstract][Full Text] [Related]
13. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
14. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290 [TBL] [Abstract][Full Text] [Related]
15. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Greggio E Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865 [TBL] [Abstract][Full Text] [Related]
16. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237 [TBL] [Abstract][Full Text] [Related]